Seminars in Hematology
Volume 45 , Pages S12-S15 , April 2008

Tissue Factor–Independent Effects of Recombinant Factor VIIa on Hemostasis

  • Cees Weeterings

      Affiliations

    • Department of Clinical Chemistry and Hematology, University Medical Center, Utrecht, The Netherlands.
    • ,
  • Ton Lisman

      Affiliations

    • Department of Clinical Chemistry and Hematology, University Medical Center, Utrecht, The Netherlands.
    • Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
    • ,
  • Philip G. de Groot

      Affiliations

    • Department of Clinical Chemistry and Hematology, University Medical Center, Utrecht, The Netherlands.
    • Corresponding Author InformationAddress correspondence to Philip G. de Groot, MD, Department of Clinical Chemistry and Hematology, University Medical Center, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.

References 

  1. Key NS, Negrier C. Coagulation factor concentrates: Past, present, and future. Lancet. 2007;370:439–448
  2. Hoyer LW. Factor VIII inhibitors. Curr Opin Hematol. 1995;2:365–371
  3. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(suppl 1):S13–S17
  4. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983;71:1836–1841
  5. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778
  6. Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev. 2007;21:223–236
  7. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost. 2006;32(suppl 1):77–85
  8. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301–2311
  9. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1:1138–1139
  10. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993;92:1207–1212
  11. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis. 1996;26(suppl 1):102–108
  12. Björquist P, Boström S. Determination of the kinetic constants of tissue factor/factor VII/factor VIIA and antithrombin/heparin using surface plasmon resonance. Thromb Res. 1997;85:225–236
  13. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood. 1994;83:38–42
  14. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547
  15. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost. 2005;3:742–751
  16. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101:1864–1870
  17. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100:1673–1685
  18. Poon MC, D'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: Results of an international survey. J Thromb Haemost. 2004;2:1096–1103
  19. Niewiarowski S, Levy-Toledano S, Caen JP. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res. 1981;23:457–463
  20. McGregor L, Hanss M, Sayegh A, Calvette JJ, Trzeciak MC, Ville D, et al. Aggregation to thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking glycoproteins IIb and IIIa. Thromb Haemost. 1989;62:962–967
  21. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem. 2001;276:21173–21183
  22. Jarvis GE, Atkinson BT, Frampton J, Watson SP. Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb. Br J Pharmacol. 2003;138:574–583
  23. Lisman T, Adelmeijer J, Heijnen HF, De Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood. 2004;103:1720–1727
  24. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381–1389
  25. Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J. 1990;265:327–336
  26. Clemetson KJ. A short history of platelet glycoprotein Ib complex. Thromb Haemost. 2007;98:63–68
  27. Weeterings C, Adelmeijer J, de Groot PG, Lisman T. Glycoprotein Ib alpha contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. J Thromb Haemost. 2007;5(suppl 2):O-S-042
  28. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: Involvement of thrombin and fibrin(ogen). Front Biosci. 2005;10:2504–2517
  29. Baglia FA, Shrimpton CN, López JA, Walsh PN. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J Biol Chem. 2003;278:21744–21750

 STATEMENT OF CONFLICT OF INTEREST: This study was supported by an unrestricted grant from Novo Nordisk.

PII: S0037-1963(08)00058-9

doi: 10.1053/j.seminhematol.2008.03.018

Seminars in Hematology
Volume 45 , Pages S12-S15 , April 2008

Article Tools

* Image Usage & Resolution